stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) Revenue growth
IDEAYA Biosciences, Inc.'s revenue growth over the twelve months to 30 September 2026 was −83.6%, down 3108.1 percentage points from fiscal 2025 (3,024.4%). Over the past ten years it has ranged from −70.1% (fiscal 2024) to 3,024.4% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 3,024.4% | 3,094.50 |
| FY2024 | −70.1% | (15.99) |
| FY2023 | −54.1% | (136.36) |
| FY2022 | 82.3% | 39.27 |
| FY2021 | 43.0% | 73.08 |
| FY2020 | −30.1% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −95.1% | (220.84) |
| Jun 2026 | 125.8% | 144.16 |
| Mar 2026 | −18.4% | (225.27) |
| Dec 2025 | 206.9% | (2,330.61) |
| 13 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BEAM Beam Therapeutics Inc. compare | 163.3% |
| TARS Tarsus Pharmaceuticals, Inc. compare | 86.3% |
| VRDN Viridian Therapeutics, Inc. compare | −62.8% |
| IDYA IDEAYA Biosciences, Inc. | −83.6% |
| DNLI Denali Therapeutics Inc. compare | −93.4% |
| TLX Telix Pharmaceuticals Limited compare | — |
| CELC Celcuity, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| ELVN Enliven Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement